Featured on the cover of "Nature-Medical"!

In 2012, Emily Whitehead, a 7-year-old child, suffered two recurrences of leukemia and his life was hanging by a thread

As the first leukemia child ever to receive CAR-T therapy, Emily's cancer cells disappeared completely after receiving multiple courses of treatment

The top priority of CAR-T therapy is the efficient use of T cells.

The CAR-T therapy for Emily targets the CD19 protein

In a type of hematological tumor called large B-cell lymphoma (LBLC), 62.

Since a single navigation is not good enough, let's add another target and let the T cell two-pronged approach ensure the effect? The most recent issue of "Nature-Medicine" demonstrated a dual-specific CAR-T therapy

▲The research appeared on the cover of the August issue of "Nature Medicine"

Many B-cell tumors also express CD22 molecules

The researchers recruited 39 patients with B-cell tumors to participate in the Phase 1 clinical trial, including 17 patients with acute lymphoblastic leukemia (B-ALL) and 22 patients with LBLC, of ​​which 38 received bispecific CAR-T therapy

▲Patients receiving the new therapy can get partial remission after 1 month of T cell reinfusion, and the condition will continue to relieve for 6 months (picture source: reference [1])

Subsequently, the researchers made a preliminary assessment of the patients after 3 months of T cell reinfusion.

▲Overall survival rate and progression-free survival rate

In addition, some indicators that show the presence of tumors will also get better with treatment

In the B-ALL group, the situation is more optimistic.

The results of the two groups indicate that CAR-T therapy for CD19-CD22 can have significant therapeutic effects on both hematological tumors, and does not require separate and multiple treatments for different targets.

Taken together, CD19 alone may not be enough to treat B-cell tumors.

Reference materials:

[1] Spiegel, JY, Patel, S.